

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of Cayman Islands with limited liability)

(Stock Code: 6833)

SUPPLEMENTAL ANNOUNCEMENT ON DISCLOSEABLE TRANSACTION IN RELATION TO THE SECRET NEEDLE TECHNOLOGICAL DEVELOPMENT AGREEMENTS

Reference is made to the announcement of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 7 November 2022 on the discloseable transaction in relation to the Secret Needle Technological Development Agreements (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

This announcement is made to provide supplemental information on the identities of the ultimate beneficial owners of Beijing Nuokangda.

INFORMATION ON THE BEIJING NUOKANGDA

As at the date of this announcement, to the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, the shareholders with 10.00% or more equity interest, directly and indirectly, in Beijing Nuokangda are Dr. Tao Xiumei (陶秀梅), Hangzhou Tairan Hengxin Equity Investment Fund Partnership (Limited Partnership)* (杭州泰然横欣股权投资基金合夥企业(有限合伙)) (“**Tairan Hengxin**”), Ms. Wang Chunpeng (王春鹏) and Mr. Chen Peng (陈鹏), who hold equity interest in Beijing Nuokangda as to approximately 25.70%, 10.99%, 10.25% and 10.09%, respectively. In addition to above shareholders, Beijing Nuokangda has twenty-two other shareholders, each of whom holds less than 10.00% equity interest in Beijing Nuokangda as at the date of this announcement.

Tairan Hengxin has a total of twenty limited partners and its general partner is Chongqing Tairan Tianhe Equity Investment Fund Management Co., Ltd.* (重慶泰然天合股權投資基金管理有限公司) (“**Tairan Tianhe**”). The shareholders of Tairan Tianhe with 10.00% or more equity interest, directly and indirectly are Mr. Pan Baofeng (潘寶峰) and Mr. Yao Shuijin (姚水金), who hold equity interest in Tairan Tianhe as to 51.00% and 49.00%, respectively.

Save for Chongqing Zhongke Anxincheng Asset Management Co., Ltd.* (重慶中科安信誠資產管理有限公司) (“**Chongqing Zhongke**”), who holds 43.74% equity interest in Tairan Hengxin, there is no other limited partner who holds 10.00% or more partnership interest in Tairan Hengxin. Chongqing Zhongke’s ultimate beneficial owners with 10.00% or more equity interest are Mr. Huang Yifeng (黃一峰), Ms. Wang Xiaoqin (王小琴) and Mr. Yu Zongchang (余宗常), who indirectly hold equity interest in Chongqing Zhongke as to approximately 65.21%, 22.64%, and 10.59%, respectively.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquires, Beijing Nuokangda and its ultimate beneficial owners are third parties independent of the Company and the connected persons of the Company.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 7 December 2022

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.

* *For identification purpose only*